MAPK1 and synovial sarcoma: These findings align with prior studies indicating the anti-inflammatory effects of pitavastatin on interleukin-1β-induced inflammation in SW982 human synovial sarcoma cells via the deactivation of p38, ERK, and JNK pathway phosphorylation [63].